Focus: Jerusalem Pharmaceuticals is a mid-sized Israeli pharmaceutical company founded in 1969, primarily focused on developing drugs for the Middle East region with a current workforce of 201-500 employees. The company is publicly listed and maintains active research programs across neurology and other therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Jerusalem Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Phase 4 asset indicating regulatory approval and commercialization stage maturity.
Help build intelligence for Jerusalem Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Jerusalem Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Phase 3 program developed during pandemic, though current market status and commercial traction unknown.
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo